Efficacy and Safety of Up to 8 Years of Long-term Growth Hormone Treatment in Short Children Born Small for Gestational Age in Japan: Analysis of the Subpopulation According to the Japanese Guideline

• Published in: Clinical Pediatric Endocrinology Vol. 21; no. 4; pp. 57 - 68
• Main Authors: Tanaka, Toshiaki, Seino, Yoshiki, Tada, Hiroshi, Ohki, Nobuhiko, Fujieda, Kenji, Mishina, Jun, Takata, Ami, Saito, Susumu, Yokoya, Susumu
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Pediatric Endocrinology 2012
• Subjects: Genotropin; GH treatment; Original; puberty; SGA short stature; small for gestational age (SGA) clinical study; small for gestational age (SGA) clinical study; SGA short stature; puberty; Genotropin; GH treatment
• ISSN: 0918-5739; 1347-7358
• DOI: 10.1297/cpe.21.57

The efficacy and safety of 8 yr of GH treatment was assessed in 44 Japanese children with small for gestational age (SGA) short stature who met the criteria for GH treatment initiation (height SD score (SDS) <–2.5 SD) of the Japanese guidelines. Height SDS in subjects improved throughout the study period, and average height SDS improved from –3.5 to –1.6 and from –3.4 to –1.9 in the 0.033/0.067 mg and 0.067/0.067 mg groups, respectively, after 8 yr of GH treatment. Delta height SD was approximately +2 after 4 yr of treatment, and Δ IGF-1 showed a significant positive correlation with Δ height SD after both 1 and 2 yr (r = 0.415 and 0.488, respectively) of treatment. There was no correlation between the age at the start of treatment and age at onset of puberty, and the median age at the onset of puberty in the subjects was almost the same as that in healthy children. In conclusion, clinically significant improvements in the height SDS was confirmed in short children born SGA after 8 yr of GH treatment without any safety problems.